IMPORTANCE Psoriasis is a chronic disease requiring long-term management; understanding the long-term safety profiles of psoriasis treatments, such as bimekizumab, is important.

OBJECTIVE To evaluate the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis.

DESIGN, SETTING, AND PARTICIPANTS Safety data were pooled from a cohort of patients from 4 phase 2 randomized clinical trials (BE ABLE 1, BE ABLE 2, PS0016, and PS0018) and 4 phase 3 randomized clinical trials (BE VIVID, BE READY, BE SURE, and BE BRIGHT) to include 2 years of study treatment. Data were obtained on adults with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index level ≥12, ≥10% body surface area affected by psoriasis, and an Investigator’s Global Assessment score ≥3 on a 5-point scale) who were eligible for systemic psoriasis therapy and/or phototherapy.

INTERVENTIONS Included patients received 1 or more doses of bimekizumab during the phase 2 or phase 3 trials.

MAIN OUTCOMES AND MEASURES Treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs leading to treatment discontinuation are reported using exposure-adjusted incidence rates (EAIRs) per 100 person-years.

RESULTS A total of 1789 patients (1252 [70.0%] men; mean [SD] age, 45.2 [13.5] years) were treated with 1 or more doses of bimekizumab across the phase 2/3 trials and were included in these analyses; total bimekizumab exposure was 3109.7 person-years. TEAEs occurred at an EAIR of 202.4 per 100 person-years and did not increase with longer duration of bimekizumab exposure. The 3 most frequently reported TEAEs were nasopharyngitis (19.1 per 100 person-years; 95% CI, 17.4-20.9 per 100 person-years), oral candidiasis (12.6 per 100 person-years; 95% CI, 11.3-14.0 per 100 person-years), and upper respiratory tract infection (8.9 per 100 person-years; 95% CI, 7.8-10.1 per 100 person-years). Most oral candidiasis events were mild or moderate; 3 events led to discontinuation. The EAIRs of inflammatory bowel disease (0.1 per 100 person-years; 95% CI, 0.0-0.3 per 100 person-years), adjudicated suicidal ideation and behavior (0.0 per 100 person-years; 95% CI, 0.0-0.2 per 100 person-years), and adjudicated major adverse cardiac events (0.5 per 100 person-years; 95% CI, 0.3-0.8 per 100 person-years) were low.

CONCLUSIONS AND RELEVANCE In these pooled analyses of data from a cohort of patients from 8 randomized clinical trials, bimekizumab was well tolerated aside from an increased incidence of mild to moderate oral candidiasis. No safety signals were observed compared with previous reports, and there was no increased risk of AEs with longer duration of bimekizumab exposure.
The chronic nature of psoriasis can place a substantial burden on patients’ health and quality of life. Long-term clinical trial data are valuable for evaluating the safety profiles of psoriasis treatments. Biologic therapies that inhibit key cytokines involved in psoriasis pathogenesis, such as interleukin (IL)-23, tumor necrosis factor, and IL-17A, are mainstays of treatment for patients with moderate to severe plaque psoriasis, and have well-established safety profiles.

Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab has previously demonstrated superior efficacy vs placebo, ustekinumab (anti–IL-12/23), adalimumab (anti–tumor necrosis factor), and secukinumab (anti–IL-17A) for the treatment of patients with moderate to severe plaque psoriasis.

Safety data reported from the first year of clinical trials in the bimekizumab treatment for plaque psoriasis clinical program demonstrated that bimekizumab is well tolerated, with a safety profile in line with other anti–IL-17 biologics, aside from an increased incidence of mild to moderate oral candidiasis, as a result of the protective roles of IL-17A and IL-17F against fungal infections at the oral mucosa.

We report safety data from 4 phase 2 randomized clinical trials and 4 phase 3 randomized clinical trials in the bimekizumab plaque psoriasis clinical program, pooled to include 2 years of study treatment, to assess the longer-term safety profile of bimekizumab in patients with moderate to severe plaque psoriasis.

Methods

Patient Population

Safety data were pooled from 4 phase 3 randomized clinical trials (BE VIVID [NCT03370133], BE READY [NCT03410992], BE SURE [NCT03412747], and BE BRIGHT [NCT03558790]) and 4 phase 2 randomized clinical trials (BE ABLE 1 [NCT02905006], BE ABLE 2 [NCT03010527], PS0016 [NCT03025542], and PS0018 [NCT03230292]). The data cutoff for the ongoing BE BRIGHT trial was November 9, 2020; the last ongoing patient in BE BRIGHT reached 2 years of study treatment on this date. All other trials included herein were completed.

Full inclusion and exclusion criteria have been described. Eligible patients for all trials were adults with moderate to severe plaque psoriasis, with a baseline Psoriasis Area and Severity Index (PASI) score greater than or equal to 12, 10% or more of body surface area affected by psoriasis, and an Investigator’s Global Assessment score greater than or equal to 3 on a 5-point scale, who were eligible for systemic psoriasis therapy and/or phototherapy. Patients with active symptomatic inflammatory bowel disease (IBD), a recent (<6 months before screening) myocardial infarction or stroke, an active tuberculosis (TB) infection, or a high risk of acquiring a TB infection were excluded. For phase 2 trials, patients with suicidal ideation less than 6 months before screening or a lifetime history of suicide attempts were excluded. For phase 3 trials, patients with active suicidal ideation less than 1 month or a suicide attempt less than 5 years before screening were excluded.

Findings

In this cohort study including 1789 patients receiving bimekizumab, pooled data on 2 years of study treatment from 4 phase 2 randomized clinical trials and 4 phase 3 randomized clinical trials identified no safety signals. The incidence of adverse events did not increase with longer duration of exposure to bimekizumab.

Meaning

These results, pooled to include 2 years of treatment, suggest that bimekizumab is well tolerated among patients with moderate to severe plaque psoriasis.

Study Designs

The trials were conducted in accordance with the principles of the Declaration of Helsinki and approved by an independent review board and independent ethics committee. All participants provided informed written consent. Reporting in this study followed the applicable portions of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Trials included in these analyses are summarized in eTable 1 in the Supplement. Study designs for BE VIVID, BE READY, and BE SURE were published previously. The BE VIVID 52-week, randomized, double-blind, multicenter trial randomized patients to bimekizumab, 320 mg, every 4 weeks (Q4W), ustekinumab (per labeled dosing), or placebo to week 16 followed by bimekizumab, 320 mg, Q4W to week 52. The BE READY 56-week, randomized withdrawal, double-blind, multicenter trial randomized patients to bimekizumab, 320 mg, Q4W or placebo to week 16. At week 16, bimekizumab-treated patients who achieved a 90% or greater reduction from baseline in their PASI (PASI 90) score were rerandomized to bimekizumab, 320 mg, Q4W, bimekizumab, 320 mg, every 8 weeks (Q8W), or placebo to week 56. Week 16 PASI 90 nonresponders entered a 12-week bimekizumab, 320 mg, Q4W open-label escape group. The BE SURE 56-week, randomized, double-blind, multicenter trial randomized patients to bimekizumab, 320 mg, Q4W, bimekizumab, 320 mg, Q4W to week 16 then Q8W to week 56, or adalimumab (per labeled dosing) to week 24 followed by bimekizumab, 320 mg, Q4W to week 56. Patients completing each phase 3 trial were eligible to enroll in the BE BRIGHT open-label extension and received bimekizumab, 320 mg, Q4W or Q8W, depending on treatment, dose, and PASI response on feeder trial completion.

Study designs for BE ABLE 1 and BE ABLE 2 phase 2b trials have also been published. The 12-week BE ABLE 1 randomized, double-blind, dose-ranging trial randomized patients to placebo or bimekizumab Q4W at doses of 64 mg, 160 mg, 160 mg with a 320-mg loading dose at baseline, 320 mg, or 480 mg. On BE ABLE 1 completion, patients could enroll in the BE ABLE 2 48-week open-label extension. Treatment allocation in BE ABLE 2 depended on dosing in BE ABLE 1 and week 12 PASI response. PS0016 was a 28-week, phase 2a, randomized, double-blind, multicenter trial. Randomized patients received bimekizumab, 320 mg, at baseline and week 4 then placebo at week 16, or bimekizumab, 320 mg, at baseline, week 24.
4, and week 16.26 On completion, eligible patients could enroll in the 48-week PS0018 open-label extension, in which patients received bimekizumab, 160 mg, Q4W and, at the investigators’ discretion, could increase the dose to 320 mg Q4W if PASI 50 to less than PASI 75 was achieved at week 12 or later.

Safety Evaluations
Treatment-emergent adverse events (TEAEs), serious AEs, and TEAEs leading to discontinuation are reported. TEAEs were defined as AEs that occurred during exposure to treatment including less than or equal to 140 days after the last dose. Serious AEs were defined as any AE that led to 1 or more of the following: death, life-threatening event, substantial or persistent disability or incapacity, congenital anomaly or birth defect (including any occurring in a fetus), important medical event, and initial or prolongation of hospitalization. TEAEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA), version 19.0. The intensity of AEs was assessed by the investigators as mild, moderate, or severe, independently from the seriousness.

Safety topics of interest were infections (serious, opportunistic, TB, and fungal), malignant neoplasms, major adverse cardiac events, neutropenia, suicidal ideation and behavior (SIB), IBD, hypersensitivity (including anaphylactic, hypersensitivity, and injection site reactions), and elevated liver enzyme/liver function test results.

Cardiovascular TEAEs were reviewed and adjudicated by an independent cardiovascular clinical event adjudication committee. Predefined neuropsychiatric TEAEs and prespecified questionnaire scores were assessed by an independent neuropsychiatric adjudication committee to determine events that met SIB criteria. Assessments and monitoring of SIB were performed using the Columbia Suicide Severity Rating Scale.28

Opportunistic infections were predefined using company conventions. During the trials, patients were screened to evaluate TB signs, symptoms, and possible exposure (eTable 2 in the Supplement). If a patient developed evidence of active or latent TB, study treatment was stopped immediately and patients were referred to a TB specialist for further evaluation.

Statistical Analysis
Pooled safety data were assessed for all patients who received 1 or more bimekizumab doses in the phase 2/3 trials (phase 2/3 total) and in the phase 3 trials only (phase 3 total). For patients who switched to bimekizumab from placebo, ustekinumab, or adalimumab, only TEAEs that occurred during exposure to bimekizumab are reported. Safety data were also analyzed for patients who received bimekizumab, 320 mg, Q4W or Q8W in the phase 3 trials. TEAEs were attributed to the dose most recently received before the TEAE date of onset.

All TEAEs were evaluated based on exposure-adjusted incidence rates (EAIRs), defined as the number of patients with a specific AE adjusted for the duration of exposure. EAIRs are reported per 100 person-years with associated 95% CIs. Data analysis was conducted using SAS, version 9.4 (SAS Institute LLC).

Results

Patient Population
Of the 1789 patients who received 1 or more doses of bimekizumab in the phase 2/3 trials (eFigure in the Supplement), 1252 were men (70.0%) and 537 were women (30.0%); mean (SD) age was 45.2 (13.5) years. Baseline demographic and other characteristics were similar between bimekizumab dose groups and were representative of patients with plaque psoriasis eligible for biologic therapy (eTable 3 in the Supplement).

In total, 1789 patients received 1 or more doses of bimekizumab across the phase 2/3 trials (eFigure in the Supplement); total bimekizumab exposure was 3109.7 person-years and median bimekizumab duration was 673.0 days (range, 1-1037). Of these patients, 1495 were treated with 1 or more doses of bimekizumab in the phase 3 trials; total bimekizumab exposure was 2780.8 person-years and median bimekizumab duration was 730.0 days (range, 23-1037) (Table 1).

Overall Safety
TEAEs occurred at an EAIR of 202.4 per 100 person-years in the phase 2/3 trials (Table 1) and did not increase with longer duration of bimekizumab exposure (weeks 0-16: 324.7 per 100 person-years; 95% CI, 305.6-344.7 per 100 person-years; weeks 16-52: 225.5 per 100 person-years; 95% CI, 212.8-238.7 per 100 person-years; weeks 52-104: 149.1 per 100 person-years; 95% CI, 139.4-159.3 per 100 person-years) (Figure 1A). The overall EAIR of TEAEs was lower in patients treated with bimekizumab, 320 mg, Q8W (141.4 per 100 person-years; 95% CI, 129.6-153.9 per 100 person-years) than with bimekizumab, 320 mg, Q4W (219.6 per 100 person-years; 95% CI, 207.3-232.3 per 100 person-years) (Table 1).

In the phase 2/3 trials, serious TEAEs occurred at a rate of 5.9 per 100 person-years (95% CI, 5.1-6.9 per 100 person-years) and EAIRs were consistent throughout the observed treatment period (weeks 0-16: 6.1 per 100 person-years; 95% CI, 4.2-8.6 per 100 person-years; weeks 16-52: 6.8 per 100 person-years; 95% CI, 5.3-8.6 per 100 person-years; weeks 52-104: 5.6 per 100 person-years; 95% CI, 4.3-7.1 per 100 person-years) (Figure 1B). The EAIR of discontinuations due to a TEAE was 3.8 per 100 person-years and was lower during the second year of treatment compared with the first. EAIRs decreased over the observed treatment period (weeks 0-16: 6.9 per 100 person-years; 95% CI, 4.8-9.5 per 100 person-years; weeks 16-52: 4.9 per 100 person-years; 95% CI, 3.6-6.4 per 100 person-years; weeks 52-104: 2.1 per 100 person-years; 95% CI, 1.4-3.1 per 100 person-years). (Figure IC). Most TEAEs were mild or moderate; severe TEAEs occurred at a rate of 5.4 per 100 person-years. The EAIRs of severe TEAEs did not increase with longer duration of bimekizumab exposure (weeks 0-16: 6.3 per 100 person-years; 95% CI, 4.4-8.8 per 100 person-years; weeks 16-52: 6.6 per 100 person-years; 95% CI, 5.2-8.4 per 100 person-years; weeks 52-104: 5.5 per 100 person-years; 95% CI, 4.2-7.0 per 100 person-years) (Figure ID). The most frequently reported TEAEs by MedDRA-preferred term were nasopharyngitis (19.1 per 100 person-years; 95% CI, 17.4-20.9), oral candidiasis (12.6 per 100 person-years; 95% CI, 11.3-14.0), and upper
Table 1. Summary of Treatment Exposure and TEAEs in Bimekizumab-Treated Patients in the Phase 2 and Phase 3 Trials

| Variable | EAIR per 100 person-years (95% CI) | Phase 3 (wk 0-16)b | Phase 3 | Bimekizumab, total (n = 1495) |
|----------|-----------------------------------|---------------------|---------|-----------------------------|
| Total exposure, person-years | 51.6 | 207.7 | 1863.6 | 879.8 | 2740.8 | 3109.7 |
| Exposure, d | | | | | | |
| Mean (SD) | 107.4 (16.8) | 110.6 (7.3) | 456.3 (262.5) | 342.2 (236.1) | 659.0 (213.6) | 608.5 (232.6) |
| Median (range) | 112.0 (28-120) | 112.0 (28-122) | 455.5 (23-1017) | 293.0 (1-869) | 730.0 (23-1017) | 673.0 (1-1017) |
| Any TEAE | 305.8 (276.4-337.6) | 219.6 (207.3-232.3) | 141.4 (129.6-153.9) | 192.7 (182.5-203.3) | 202.4 (192.6-212.6) |
| Severe TEAEs | 7.8 (2.1-19.9) | 3.9 (1.7-7.6) | 5.3 (4.3-6.5) | 4.8 (3.4-6.5) | 5.0 (4.2-5.9) | 5.4 (4.6-6.3) |
| TEAEs leading to discontinuation | 13.8 (5.6-28.5) | 5.3 (2.7-9.5) | 3.6 (2.8-4.5) | 2.7 (1.8-4.1) | 3.3 (2.7-4.1) | 3.8 (3.1-4.6) |
| Treatment-related TEAEsc | 30.7 (17.2-50.7) | 80.0 (67.5-94.2) | 43.4 (39.8-47.1) | 28.9 (25.0-33.2) | 35.5 (32.8-38.3) | 35.4 (32.9-38.0) |
| Serious TEAEs | 7.8 (2.1-20.0) | 5.3 (2.7-9.5) | 6.2 (5.1-7.4) | 5.3 (3.8-7.0) | 5.9 (5.0-6.9) | 5.9 (5.1-6.9) |
| TEAEs leading to death | 1.9 (0.0-10.8) | 0.5 (0.0-2.7) | 0.3 (0.1-2.7) | 0.3 (0.1-2.7) | 0.3 (0.2-0.6) | 0.4 (0.2-0.6) |

Abbreviations: EAIR, exposure-adjusted incidence rate; Q4W, every 4 weeks; Q8W, every 8 weeks; TEAE, treatment-emergent adverse event.

a For patients who received both Q4W and Q8W bimekizumab doses during the trials, TEAEs were assigned to the dose most recently received before the date of onset of the TEAE. Patients who received both bimekizumab, 320 mg, Q4W and Q8W at different times in the trials are included in the total population count of each treatment group, but only once in each bimekizumab total group. Therefore, the total number of patients in both the Q4W and Q8W groups exceeds the total number of patients in the bimekizumab total groups. The data cutoff for the ongoing BE BRIGHT trial was November 9, 2020.

b Data are reported for events that occurred during the initial 16-week treatment period of the BE VIVID and BE READY placebo-controlled phase 3 randomized clinical trials, using a different pool of patients to the longer-term analyses.

c Assessed by the investigators as related to treatment.

Figure 1. Incidence Rates of Treatment-Emergent Adverse Events (TEAEs) by Treatment Period

A TEAEs overall

B Serious TEAEs

C TEAEs leading to discontinuation

D Severe TEAEs

Data are reported as the exposure-adjusted incidence rate (EAIR) per 100 person-years for TEAEs that occurred during the initial 16-week treatment period of the phase 2/3 trials (weeks 0-16), during the maintenance period (weeks 16-52) and during the second year (weeks 52-104). Error bars represent 95% CIs.
Table 2. Incidence Rates of TEAEs of Interest

| Variable                        | EAIR per 100 person-years (95% CI) |
|---------------------------------|-----------------------------------|
|                                 | Phase 3                           | Phase 2,3                           |
|                                 | Bimekizumab, 320 mg Q4W (n = 1456) | Bimekizumab, total (n = 1789)       |
|                                 | Bimekizumab, 320 mg Q8W (n = 330) |                                   |
|                                 | Bimekizumab, total (n = 1495)     |                                   |
| Serious infections               | 1.4 (0.9-2.1)                     | 1.0 (0.7-1.4)                      |
| Active tuberculosis              | 0.0                              | 0.0                               |
| Fungal infections                | 25.7 (23.2-28.4)                  | 20.1 (18.4-22.0)                   |
| Candida infections               | 18.9 (16.8-21.1)                  | 14.2 (12.8-15.7)                   |
| Oral candidiasis                 | 16.4 (14.5-18.5)                  | 12.6 (11.3-14.0)                   |
| Oropharyngeal candidiasis       | 1.1 (0.7-1.7)                     | 0.8 (0.6-1.2)                      |
| Skin candidiasis                | 0.7 (0.4-1.2)                     | 0.7 (0.4-1.0)                      |
| Vulvovaginal candidiasis        | 0.8 (0.5-1.3)                     | 0.6 (0.3-0.9)                      |
| Esophageal candidiasis          | 0.2 (0.1-0.6)                     | 0.2 (0.1-0.4)                      |
| Tinea infections                | 3.0 (2.3-4.0)                     | 2.7 (2.1-3.3)                      |
| Fungal infections NECc          | 3.8 (2.9-4.8)                     | 3.1 (2.5-3.7)                      |
| Inflammatory bowel disease      | 0.2 (0.0-0.5)                     | 0.1 (0.0-0.3)                      |
| Adjudicated MACE                | 0.5 (0.3-1.0)                     | 0.5 (0.3-0.8)                      |
| Malignant neoplasms             | 0.6 (0.3-1.1)                     | 0.8 (0.5-1.2)                      |
| Excluding NMSC                  | 0.3 (0.1-0.7)                     | 0.5 (0.2-0.8)                      |
| NMSC                             | 0.3 (0.1-0.7)                     | 0.3 (0.2-0.6)                      |
| Adjudicated SIB                 | 0.1 (0.0-0.3)                     | 0.0 (0.0-0.2)                      |
| Neutropenia                      | 0.8 (0.5-1.3)                     | 0.8 (0.6-1.2)                      |
| Hepatic events                  | 3.7 (2.9-4.7)                     | 4.3 (3.6-5.2)                      |
| Elev. liver enzyme levelsd      | 3.1 (2.4-4.1)                     | 3.6 (3.0-4.4)                      |
| Serious hypersensitivity reactionsd| 0.2 (0.0-0.5)                  | 0.2 (0.1-0.4)                      |
| Injection site reactions        | 2.7 (2.0-3.6)                     | 2.3 (1.8-2.9)                      |

Abbreviations: EAIR, exposure-adjusted incidence rate; MACE, major adverse cardiac event; NEC, not elsewhere classified; NMSC, nonmelanoma skin cancer; Q4W, every 4 weeks; Q8W, every 8 weeks; SIB, suicidal ideation and behavior; TEAE, treatment-emergent adverse event.

For patients who received both Q4W and Q8W bimekizumab doses during the trials, TEAEs were assigned to the dose most recently received before the date of onset of the TEAE. Patients who received both bimekizumab, 320 mg, Q4W and Q8W at different times in the trials are included in the total population count of each treatment group, but only once in each bimekizumab total group. Therefore, the total number of patients in both the Q4W and Q8W groups exceeds the total number of patients in the bimekizumab total groups. The data cutoff for the ongoing BE BRIGHT trial was November 9, 2020.

Deaths
In total, 11 deaths (0.4 per 100 person-years) were reported for patients receiving bimekizumab in the phase 2/3 trials (Table 1). Causes of death were reported under the following MedDRA-preferred terms, each for 1 patient, unless otherwise specified: cardiopulmonary failure, myocardial infarction, cardiac arrest (3 patients), death (unknown cause, 3 months after last bimekizumab dose), brain neoplasm, completed suicide, dyspnea, chronic obstructive pulmonary disease, circulatory collapse (2 patients), respiratory failure, and hypovolemic shock. No deaths were assessed by the investigators as related to treatment.

Infections
The EAIR of infections was 96.7 per 100 person-years. The EAIR of serious infections was low (phase 2/3 trials: 1.0 per 100 person-years; 95% CI, 0.7-1.4 per 100 person-years), and in the phase 3 trials was lower with bimekizumab, 320 mg, Q8W (0.3 per 100 person-years; 95% CI, 0.1-1.0 per 100 person-years) compared with Q4W (1.4 per 100 person-years; 95% CI, 0.9-2.1 per 100 person-years) (Table 2). The incidence of serious infections did not increase with a longer duration of bimekizumab exposure (weeks 0-16: 1.0 per 100 person-years; 95% CI, 0.2-2.9 per 100 person-years; 1 year: 1.4 per 100 person-years; 95% CI, 0.9-2.0 per 100 person-years; 2 years: 1.0 per 100 person-years; 95% CI, 0.7-1.4 per 100 person-years) (Figure 2A). The most common serious infection was cellulitis (4 events). No cases of active TB were reported (Table 2).

The overall EAIR of opportunistic infections was 1.2 per 100 person-years (95% CI, 0.9-1.7). Almost all opportunistic infections reported with bimekizumab were localized mucocutaneous fungal infections predefined as opportunistic by company convention, except for 1 serious case of ophthalmic herpes zoster that resolved with treatment and did not lead to discontinuation.
Fungal infections occurred at a rate of 20.1 per 100 person-years (95% CI, 18.4-22.0) (phase 2/3). Most were *Candida* infections (14.2 per 100 person-years; 95% CI, 12.8-15.7 per 100 person-years); EAIRs for other fungal infections, including *Tinea* infections, were low (Table 2).

**Candidiasis**

*Candida* infections were predominantly reported as oral candidiasis (12.6 per 100 person-years; 95% CI, 11.3-14.0 per 100 person-years) (Table 2). Of the patients in the phase 2/3 trials, 275 of 1789 (15.4%) reported an oral candidiasis event in the first year and 131 of 1435 (9.1%) during the second year. The cumulative EAIR of oral candidiasis decreased with a longer duration of bimekizumab exposure as shown in Figure 2B (weeks 0-16: 25.3 per 100 person-years; 95% CI, 19.9-31.8 per 100 person-years; 1 year: 16.4 per 100 person-years; 95% CI, 14.5-18.5 per 100 person-years; 2 year: 12.6 per 100 person-years; 95% CI, 11.3-14.0 per 100 person-years). In the phase 2/3 trials, the incidence of oral candidiasis decreased by treatment period as shown in Figure 3A (weeks 0-16: 24.7 per 100 person-years; 95% CI, 20.6-29.3 per 100 person-years; weeks 16-52: 18.9 per 100 person-years; 95% CI, 16.3-21.8 per 100 person-years; weeks 52-104: 12.3 per 100 person-years; 95% CI, 10.3-14.6 per 100 person-years). Most oral candidiasis events were mild or moderate in severity, 5 were reported as severe (0.2 per 100 person-years; 95% CI, 0.1-0.4), and none were reported as serious.

In the phase 3 trials, the EAIR of oral candidiasis was lower for patients who received bimekizumab, 320 mg, every 4 weeks (Q4W) vs bimekizumab, 320 mg, Q8W (9.6 per 100 person-years; 95% CI, 7.6-12.0 per 100 person-years) (Table 2). In BE SURE and BE READY, in which both bimekizumab Q4W and Q8W maintenance dosing regimens were possible, the EAIR of oral candidiasis was lower in the second year compared with the first for patients who received either bimekizumab Q4W or Q8W continuous maintenance dosing. In addition, the EAIR of oral candidiasis was lower in each period for patients who received continuous Q8W bimekizumab maintenance dosing compared with continuous Q4W maintenance dosing (weeks 16-52, Q8W: 18.6 per 100 person-years; 95% CI, 12.0-27.5 per 100 person-years; Q4W: 24.6 per 100 person-years; 95% CI, 14.1-
40.0 per 100 person-years; weeks 52-104, Q8W: 10.6 per 100 person-years; 95% CI, 6.4-16.5 per 100 person-years; Q4W: 13.0 per 100 person-years; 95% CI, 6.2-23.8 per 100 person-years) (Figure 3B).

Over 2 years of treatment, 170 patients (9.5%) reported 1 incidence of oral candidiasis, 88 (4.9%) reported 2 incidences, 33 (1.8%) reported 3 incidences, 22 (1.2%) reported 4 incidences, and 20 (1.1%) reported 5 or more incidences (Figure 3D). The method of oral candidiasis treatment was at the discretion of the investigators and most patients with oral candidiasis were treated with nystatin and/or fluconazole. The median treatment duration with antifungal therapies was 12.0 days (IQR, 7.0-22.0 days). Most events were resolved with treatment; 3 patients (0.2%) with oral candidiasis discontinued bimekizumab.

In the phase 2/3 trials, 2 patients (0.1%) with esophageal candidiasis, 1 (<0.1%) with oropharyngeal candidiasis, and 1 (<0.1%) with skin Candida discontinued bimekizumab treatment. Of these, 1 patient receiving bimekizumab, 320 mg, Q4W reported a serious, severe case of esophageal candidiasis; this patient was hospitalized, received antifungal therapy, and the infection resolved after 14 days. No other serious Candida infections were reported.

**Inflammatory Bowel Disease**

The EAIR of IBD was low (0.1 per 100 person-years; 95% CI, 0.0-0.3 per 100 person-years) and did not increase with longer duration of bimekizumab exposure (weeks 0-16: 0.3 per 100 person-years; 95% CI, 0.0-1.8 per 100 person-years; 1 year: 0.1; 95% CI, 0.0-0.3 per 100 person-years; 2 years: 0.1 per 100 person-years; 95% CI, 0.0-0.3 per 100 person-years) (Figure 2C). In total, 4 cases were reported (2 Crohn disease, 1 colitis, and 1 ulcerative colitis); all occurred in the phase 3 trials (Table 2). Three cases of IBD led to discontinuation of treatment, 2 of which were considered by the investigators to be related to treatment.

**Malignant Neoplasms**

In the phase 2/3 trials, excluding nonmelanoma skin cancer, there were 14 incidences of cancer (0.5 per 100 person-years; 95% CI, 0.2-0.8 per 100 person-years) (Table 2); the EAIR remained low with a longer duration of bimekizumab exposure (Figure 2D). Overall, including nonmelanoma skin cancer, 26 cancers were reported in 24 patients (0.8 per 100 per 100 person-years; 95% CI, 0.5-1.2 per 100 person-years) (Table 2). No incidences of cancer were assessed by the investigators as related to treatment.

**Other TEAEs of Interest**

The EAIR of adjudicated major adverse cardiac events in the phase 2/3 trials was 0.5 per 100 person-years (95% CI, 0.3-0.8 per 100 person-years) (Table 2) and did not increase with a longer duration of bimekizumab exposure (Figure 2E). The EAIR of...
neutropenia was 0.8 per 100 person-years (95% CI, 0.6-1.2 per 100 person-years) (Table 2); most cases were mild or moderate and 2 led to discontinuation of treatment. The EAIR of serious hypersensitivity reactions was low (0.2 per 100 person-years; 95% CI, 0.1-0.4 per 100 person-years) (Table 2). Injection site reactions occurred at an EAIR of 2.3 per 100 person-years (95% CI, 1.8-2.9 per 100 person-years); all cases were mild or moderate and none led to discontinuation. Hepatic events occurred at an EAIR of 4.3 per 100 person-years (95% CI, 3.6-5.2 per 100 person-years) and were predominantly reports of increased liver enzyme levels (Table 2). The increased liver enzyme levels observed mostly had alternative causes and were reversed with either continued treatment or shortly after discontinuation, such that bimekizumab was still at therapeutic levels. Overall, the incidence of adjudicated SIB was low (0.0 per 100 person-years; 95% CI, 0.0-0.2 per 100 person-years) (Table 2; Figure 2F); 1 patient receiving bimekizumab, 320 mg, Q4W recorded a positive electronic Columbia Suicide Severity Rating Scale response to question 4 (active suicidal ideation with some intent to act), which was adjudicated as SIB and led to discontinuation of treatment. One event of completed suicide in a patient receiving bimekizumab was adjudicated as SIB after the data cutoff for these analyses and therefore is not included in the EAIR of SIB reported herein. The patient had no known psychiatric medical history, but financial issues were reported as risk factors; the event was assessed by the investigators as not related to treatment.

Discussion

In these analyses, data were pooled to include 2 years of study treatment for patients with moderate to severe plaque psoriasis who received bimekizumab across 4 phase 2 randomized clinical trials and 4 phase 3 randomized clinical trials. Overall, the incidence of TEAEs decreased with a longer duration of bimekizumab exposure. In the phase 3 trials, the incidence of TEAEs was lower in patients treated with bimekizumab, 320 mg, Q8W compared with Q4W. The rate of discontinuation due to TEAEs was low.

Nasopharyngitis, oral candidiasis, and upper respiratory tract infection were the most common TEAEs reported with bimekizumab. The risk of infections for patients with psoriasis is higher than in the general population, and anti-IL-17 biologics may increase this risk.4,29,30 In addition, the use of biologic and systemic treatments for psoriasis may increase the risk of serious infections.31 In these analyses, the EAIR of serious infections was low (1.0 per 100 person-years), did not increase with longer exposure to bimekizumab, and was comparable with the estimated rate among patients with psoriasis in the Psoriasis Longitudinal Assessment and Registry (1.6 per 100 person-years),12 and EAIRs reported in clinical studies with other IL-17 inhibitors (secukinumab: 1.4 per 100 person-years;10,33; brodalumab: 1.0-1.3 per 100 person-years35; and ixekizumab: 1.3-2.3 per 100 person-years).8,12,34

Interleukin-17 is involved in mucosal host defenses against fungal infections; therefore, anti-IL-17 biologics can be associated with an increased risk of oral mucocutaneous candidiasis.35-39 Consistent with individual study data,17-22 oral candidiasis was one of the most common TEAEs reported with bimekizumab (12.6 per 100 person-years), and the EAIR was higher than that reported in pooled studies up to 5 years with other IL-17 inhibitors (secukinumab: 1.9 per 100 person-years33; ixekizumab: 0.8-1.2 per 100 person-years).12,34 In these pooled data, most oral candidiasis events with bimekizumab were mild to moderate in intensity, and the rate of discontinuation due to oral candidiasis was low (0.2%). The EAIR of oral candidiasis decreased with a longer duration of bimekizumab exposure and was lower with bimekizumab Q8W compared with Q4W. The EAIRs of other fungal infections were low.

Patients with psoriasis can be at increased risk of IBD.40-42 In addition, rare exacerbations of IBD have been reported with inhibitors of IL-17A.43,44 In the phase 2/3 trials, the incidence of IBD with bimekizumab was low (0.1 per 100 person-years) and similar to rates reported in a psoriasis cohort study (Crohn disease: 0.03 per 100 person-years; ulcerative colitis: 0.07 per 100 person-years),42 and other long-term anti-IL-17 clinical studies (secukinumab: 0.01-0.3 per 100 person-years;33,35 ixekizumab: 0.2 per 100 person-years).12 Cases of IBD in these pooled analyses were mild or moderate, 3 led to discontinuation, and 2 were assessed by the investigators as related to treatment. Inflammatory bowel disease events were not adjudicated for these analyses and, owing to the low incidence, it was not possible to identify specific characteristics that may have predisposed patients to develop IBD.

Psoriasis can place a substantial burden on patient quality of life, and patients may be at increased risk of depression and SIB.24,45 In these analyses, the incidence of adjudicated SIB was low and within the background rate for patients with psoriasis.46

Limitations

This study has limitations. Although these analyses report safety data for a large population of patients who received bimekizumab, the data may not fully represent a real-world population owing to the specific patient inclusion and exclusion criteria of the trials analyzed. Furthermore, the population may be too small to draw definitive conclusions for more rare events.

Conclusions

In these analyses pooled to include 2 years of treatment in a cohort of patients from 8 randomized clinical trials, bimekizumab demonstrated a favorable safety profile and no safety signals were observed. In the phase 3 trials, the incidence of AEs was lower with bimekizumab, 320 mg, Q8W compared with Q4W. Overall, bimekizumab was well tolerated in patients with moderate to severe plaque psoriasis, and there was no increased risk of AEs with longer duration of exposure.
ARTICLE INFORMATION

Accepted for Publication: March 11, 2022.
Published Online: May 11, 2022.
doi:10.1001/jamadermatol.2022.1185

Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2022 Gordon KB et al. JAMA Dermatology.

Author Affiliations: Department of Dermatology, Medical College of Wisconsin, Milwaukee (Gordon); Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, Canada (Langley); Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, United Kingdom (Wixted); Department of Dermatology, Tokyo Medical University, Tokyo, Japan (Okubo); Dermatology Clinical Research, Henry Ford Health System, Detroit, Michigan (Stein Gold); Department of Dermatology, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts (Merola); UCB Pharma, Raleigh, North Carolina (Peterson, Wixted, Cross); UCB Pharma, Braine-l’Alleud, Belgium (Deherder); Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany (Thaçi).

Author Contributions: Mr Peterson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the analysis. Concept and design: Langley, Warren, Okubo, Merola, Peterson, Cross. Acquisition, analysis, or interpretation of data: Gordon, Warren, Okubo, Stein Gold, Merola, Peterson, Wixted, Cross, Deherder, Thaçi. Drafting of the manuscript: Langley, Stein Gold, Merola, Cross. Critical revision of the manuscript for important intellectual content: Gordon, Warren, Okubo, Stein Gold, Merola, Peterson, Wixted, Cross, Deherder, Thaçi. Statistical analysis: Langley, Peterson, Cross. Administrative, technical, or material support: Langley, Merola, Wixted, Cross. Supervision: Langley, Warren, Okubo, Stein Gold, Cross, Thaçi.

Conflict of Interest Disclosures: Dr Gordon reported receiving grants and nonfinancial support from UCB Pharma during the conduct of the study; personal fees from AbbVie, Amgen, Arcutis, Dermira, Galderma, Incyte, Janssen, Kyowa Hakko Kirin, LEO Pharma, Eli Lilly, Novartis, Ortho, Pfizer, Sun, Sanofi/Genzyme, and UCB Pharma; and grants from AbbVie, BMS, Janssen, Eli Lilly, and UCB Pharma outside the submitted work. Dr Langley reported receiving grants and fees for serving on the scientific advisory board and speaking fees from AbbVie, Janssen, Novartis, Eli Lilly, LEO Pharma, UCB Pharma, Amgen, Pfizer, and Boehringer Ingelheim during the conduct of the study; and receiving grants and fees for serving on the scientific advisory board and speaking fees from AbbVie, Sun, Novartis, Eli Lilly, UCB Pharma, Boehringer Ingelheim, and Amgen outside the submitted work. Dr Warren reported receiving grants from AbbVie, Almirall, LEO Pharma, and Eli Lilly outside the submitted work; and personal fees from Novartis, UCB Pharma, UNION Therapeutics, DICE, Janssen, and LEO Pharma outside the submitted work. Dr Okubo reported receiving grants from AbbVie, Eisai, Maruho, Shiseido, and Sun Pharma; and personal fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen Pharma, Jinyoung, Kyowa Hakko Kirin, LEO Pharma, Maruho, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho, Tanabe-Mitsubishi, Torii, and UCB Pharma outside the submitted work. Dr Stein Gold reported receiving grants and speaking fees from UCB Pharma during the conduct of the study. Dr Merola reported receiving consultant fees from AbbVie, Dervant, Eli Lilly, Novartis, Janssen, UCB Pharma, Celgene, Biogen, Pfizer, and LEO Pharma outside the submitted work. Mr Peterson, Ms Wixted, Dr Cross, and Ms Deherder reported being UCB Pharma employees and shareholders. Dr Thaçi reported receiving fees for consulting and advisory board membership and nonfinancial support from UCB Pharma during the conduct of the study; lecture, consulting, and advisory board fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Eli Lilly, LEO Pharma, Novartis, and Pfizer; consulting fees from Galapagos; and grants from LEO Pharma and Novartis. No other disclosures were reported.

Funding/Support: This study was sponsored by UCB Pharma. Dr Warren is supported by the NIHR Manchester Biomedical Research Centre.

Role of the Funder/Sponsor: The funders participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Support for third-party writing assistance for this article provided by Claire Hews, PhD, and Daniel Smith, BA (Costello Medical, UK), based on the authors’ input and direction was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). We thank the patients, and the investigators and their teams who took part in this study. Susanne Wiegartz, MSc (UCB Pharma, Germany), provided publication coordination, and Natalie Nunez Gomez, MD (UCB Pharma, Germany), provided critical review.

Additional Information: The trials examined in this article (BE ABLE 1, BE ABLE 2, PSO016, PSO017, BE VIVID, BE READY, BE SURE, and BE BRIGHT) were sponsored by UCB Pharma. Underlying data from this manuscript may be requested by qualified researchers 6 months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents, which may include analysis-ready data sets, study protocol, annotated case report form, statistical analysis plan, data set specifications, and clinical study report. Before use of the data, proposals need to be approved by an independent review panel at http://www.vivi.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password-protected portal.

REFERENCES

1. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35-35. doi:10.1186/1477-7525-4-35

2. Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427. doi:10.3390/ijms18112427

3. Strober B, Greenberg JD, Karci C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4):e027535. doi:10.1136/bmjopen-2018-027535

4. Takeishi J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377-390. doi:10.1016/j.jaad.2016.07.064

5. European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis, 2004. Accessed March 31, 2022. https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-indicated-treatment-psoriasis

6. Langley RG, Elewski BE, Lebwohl M, et al; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. doi:10.1056/NEJMoa1314258

7. Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. doi:10.1056/NEJMoa1512711

8. Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase 3 randomized controlled trials. Dermatol Ther (Heidelb). 2020;10(3):431-447. doi:10.1007/s13075-020-00367-x

9. Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936-945. doi:10.1016/j.jaad.2019.11.040

10. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. doi:10.1186/s13075-019-1882-7

11. Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161-1173. doi:10.1111/jdv.16124

12. Armstrong A, Paul C, Puig L, et al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. Dermatol Ther (Heidelb). 2020;10(1):133-150. doi:10.1007/s13555-019-00340-3

13. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328. doi:10.1056/NEJMoa1503824
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis

14. Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991-1001. doi:10.1111/bcp.13185

15. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523-532. doi:10.1136/annrheumdis-2017-212127

16. Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. doi:10.3389/fimmu.2020.01894

17. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475-486. doi:10.1016/S0140-6736(21)00124-4

18. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicenter double-blind study. Br J Dermatol. Published online October 23, 2021. doi:10.1111/bjd.20827

27. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053

28. Posner K, Brown G, Stanley B, et al. The Columbia Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. doi:10.1176/appi.ajp.2011.11101704

29. Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45(3):279-286. doi:10.1111/1346-8138.14096

30. Wakkie M, de Vries E, van den Haak P, Nijsten T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol. 2011;65(6):1135-1144. doi:10.1016/j.jaad.2010.08.036

31. Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(1):961-969. doi:10.1001/jamadermatol.2015.0718

32. Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other biologics in patients with moderate to severe plaque psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277-286.e10. doi:10.1016/j.jaad.2018.03.037

32. Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other biologics in patients with moderate to severe plaque psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277-286.e10. doi:10.1016/j.jaad.2018.03.037

32. Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other biologics in patients with moderate to severe plaque psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b extension study. J Am Acad Dermatol. 2020;83(5):1367-1374. doi:10.1016/j.jaad.2020.05.105

33. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149-162. doi:10.1016/j.immuni.2011.02.012

34. Gladiador A, Wangler N, Trautwein-Weidner K, LeibundGut-Landmann S. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J Immunol. 2013;190(2):521-525. doi:10.4049/jimmunol.1202924

35. ClinicalTrials.gov. A study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in adult patients with chronic plaque psoriasis. 2017. March 31, 2022. https://clinicaltrials.gov/ct2/show/NCT03230292

36. Reich K, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate to severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase 2a randomized, multicenter double-blind study. Br J Dermatol.Published online October 23, 2021. doi:10.1111/bjd.20827

37. Armstrong AW, Buhkalo M, Blauvelt A. A clinician’s guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol. 2016;17(4):329-336. doi:10.4025/ajcd.2016.0148-6

38. Blauvelt A, Lebwohl MG, Bissonnette R. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015;135(8):1946-1953. doi:10.1038/jid.2015.144

39. Hiruma J, Harada K, Hirayama M, et al. Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infections. J Dermatol Sci. 2021;102(2):145-146. doi:10.1016/j.jdermsci.2021.02.003

40. Fu Y, Lee C-H, Chi C-C. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417-1423. doi:10.1001/jamadermatol.2018.3631

41. Egberg A, Thyssen JP, Burisch J, Colombel JF. Incidence and risk of inflammatory bowel disease in patients with psoriasis—a nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316-323. doi:10.1016/j.jid.2018.07.029

42. Egberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol.2016;175(3):487-492. doi:10.1111/bjd.14528

43. Fieldhouse KA, Ukaike S, Crowley EL, Khanna R, O’Toole A, Goedherm MJ. Inflammatory bowel disease in patients with psoriasis—nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316-323. doi:10.1016/j.jid.2018.07.029

44. Smith MK, Pai J, Panaccione R, Beck P, Ferraz JG, Joon H. Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 2019;19(1):162. doi:10.1186/s12876-019-1067-0

45. Wu KK, Armstrong AW. Suicidality among psoriasis patients: a critical evidence synthesis. G Ital Dermatol Venereol. 2019;154(1):56-63. doi:10.23736/S0399-0488.18.0612-6

46. Wu JJ, Penfold RD, Primasteta P, et al. The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol. 2017;31(7):1168-1175. doi:10.1111/jdv.14175

744 JAMA Dermatology July 2022 Volume 158, Number 7 jamadermatology.com